Analysis of ADORA2A, MTA1, PTGDS, PTGS2, NSF, and HNMT Gene Expression Levels in Peripheral Blood of Patients with Early Stages of Parkinson’s Disease

Semenova, Ekaterina I.; Partevian, Suzanna A.; Shulskaya, Marina V.; Rudenok, Margarita M.; Lukashevich, Maria V.; Baranova, Nina M.; Doronina, Olga B.; Doronina, Kseniya S.; Rosinskaya, Anna V.; Fedotova, Ekaterina Y.; Illarioshkin, Sergey N.; Slominsky, Petr A.; Shadrina, Maria I.; Alieva, Anelya Kh.

doi:https://doi.org/10.1155/2023/9412776

BioMed Research International

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 9412776 | https://doi.org/10.1155/2023/9412776

Analysis of ADORA2A, MTA1, PTGDS, PTGS2, NSF, and HNMT Gene Expression Levels in Peripheral Blood of Patients with Early Stages of Parkinson’s Disease

Ekaterina I. Semenova,¹Suzanna A. Partevian,¹Marina V. Shulskaya,¹Margarita M. Rudenok,¹Maria V. Lukashevich,¹Nina M. Baranova,²Olga B. Doronina,³Kseniya S. Doronina,³Anna V. Rosinskaya,⁴Ekaterina Y. Fedotova,⁵Sergey N. Illarioshkin,⁵and Petr A. Slominsky¹ et al.

Academic Editor: Andrei Surguchov

Received21 Sept 2023

Revised16 Oct 2023

Accepted24 Oct 2023

Published20 Nov 2023

Abstract

Parkinson’s disease (PD) is a common chronic, age-related neurodegenerative disease. This disease is characterized by a long prodromal period. In this context, it is important to search for the genes and mechanisms that are involved in the development of the pathological process in the earliest stages of the disease. Published data suggest that blood cells, particularly lymphocytes, may be a model for studying the processes that occur in the brain in PD. Thus, in the present work, we performed an analysis of changes in the expression of the genes ADORA2A, MTA1, PTGDS, PTGS2, NSF, and HNMT in the peripheral blood of patients with early stages of PD (stages 1 and 2 of the Hoehn–Yahr scale). We found significant and PD-specific expression changes of four genes, i.e., MTA1, PTGS2, NSF, and HNMT, in the peripheral blood of patients with early stages of PD. These genes may be associated with PD pathogenesis in the early clinical stages and can be considered as potential candidate genes for this disease. Altered expression of the ADORA2A gene in treated PD patients may indicate that this gene is involved in processes affected by antiparkinsonian therapy.

1. Introduction

Parkinson’s disease (PD) is a common chronic, age-related neurodegenerative disease [1, 2]. According to the data for 2015, there were more than 6 million PD patients globally [3]. Moreover, the number of individuals with PD is expected to double by 2030 [4].

The development of PD is primarily associated with the loss of dopaminergic (DAergic) neurons of the substantia nigra (SN) pars compacta, resulting in the classic motor symptoms [5]. These symptoms are tremor, rigidity, bradykinesia, and postural instability [6]. It should be noted that the manifestation of motor symptoms occurs only after the loss of about 70% of DAergic neurons, and it can begin more than 20 years from the onset of the neurodegenerative process [7, 8]. A long prodromal period is the main reason for late diagnosis of PD and, accordingly, for late initiation of therapy. In this regard, it is important to search for the genes and mechanisms that are involved in the development of the pathological process in the earliest stages of the disease. This task is also urgent because there is still no easy-to-follow laboratory diagnostic method based on biochemical parameters that could predict the risk of PD with high accuracy [9]. Early detection of PD is essential for initiating timely treatment and slowing the progression of the disease.

It is known that the main pathological processes in PD occur mainly in the central nervous system. Published data suggest that blood cells, particularly lymphocytes, may be a model for studying the processes that occur in the brain in PD. It has been shown that genes associated with DAergic signal transduction are expressed in blood cells, as well as in DAergic neurons [10–14]. In addition, some of the gene products expressed in peripheral blood may reflect molecular events associated with PD pathogenesis. Changes in mRNA and protein levels associated with ubiquitin-proteasome protein degradation [15–18], mitochondrial dysfunction [16–19], oxidative stress [18, 20], apoptosis [16, 17, 21, 22], and autophagy [23] have been described in peripheral blood cells from PD patients. Thus, analysis of individual genes expression changes at the mRNA level in peripheral blood may be important in the study of early stages of PD.

Our previous studies have resulted in the identification of potential candidate PD genes. Previously, we found a significant change in the expression of three genes associated with circadian rhythms, ADORA2A, MTA1, and PTGDS, in the peripheral blood of twins with PD [24], as well as PTGS2, associated with inflammatory processes, in fibroblast samples from twins with PD [25]. When studying mice with an MPTP-induced model of the early stage of PD, we obtained interesting results on changes in the expression of the NSF gene, the protein product of which is involved in transport processes [26]. In addition, the HNMT gene was selected by analyzing the published data. This gene encodes an enzyme of histamine metabolism, and it is noteworthy for analysis because it has been repeatedly reported that changes in the histaminergic system are observed in PD [27, 28]. Thus, in the present work, we focused on studying changes in the expression of ADORA2A, MTA1, PTGDS, PTGS2, NSF, and HNMT genes in the peripheral blood of patients with early stages of PD.

2. Materials and Methods

2.1. Patients

In the present work, 56 patients with early stages of PD (stages 1 and 2 of the Hoehn–Yahr scale; 25 men and 31 women; mean deviation years) were studied. There were 47 untreated and 9 treated patients. This sample included patients who were examined at Novosibirsk State Medical University and State Public Health Institution Primorsk Regional Clinical Hospital No. 1 in Vladivostok. For clinical assessment of PD, patients were studied using the International Uniform Assessment Scale for PD (Unified Parkinson’s Disease Rating Scale, UPDRS) [29] and Hoehn–Yahr scale [30]. Only those patients who lacked the most frequent PD-associated mutations were selected for analysis. Patients with PD who were treated received different medications with dopamine receptor agonists (Requip, Pronoran) or L-dopa (Madopar, Stalevo) either as monotherapy or in various combinations. The comparison group included 44 neurologically healthy volunteers (mean deviation years). In addition, 23 patients with various neurological diseases were selected as an additional control to the “neurological control” group (mean deviation years). A detailed description of the comparison groups is presented in our earlier work [31]. The studied patients and healthy volunteers were of Slavic origin. All blood samples were collected with the informed consent of the investigated subjects. The study was conducted in accordance with the World Medical Assembly (WMA) Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects [32]. The study was approved by the Ethics Committee of the Research Center of Neurology, Institute of Molecular Genetics of National Research Centre “Kurchatov Institute,” and Novosibirsk State Medical University.

2.2. Total RNA Isolation from Peripheral Blood and Expression Analysis of Individual Candidate Genes

Total RNA isolation from peripheral blood was performed, according to the previously described protocol [33]. After isolation, yeast tRNA at a concentration of 1 mg/mL was added to the resulting total RNA solution for protection [34]. Analysis of mRNA levels using reverse transcription and real-time PCR (TaqMan technology) was carried out in accordance with the protocols described previously [35].

2.3. Statistical and Bioinformatic Data Processing

Primer and probe sequence design was produced using Beacon designer 7.0 software (Premier Biosoft International, Palo Alto, CA, United States) and nucleotide sequences of the candidate genes MTA1, ADORA2A, PTGDS, AHCY, HNMT, NSF, and PTGS2 and housekeeping genes SARS1 and PSMD6 from the NCBI database [35]. The sequences of gene-specific primers and probes for the MTA1, ADORA2A, PTGDS, SARS1, and PSMD6 genes are listed in our previous work [24]. The sequences of gene-specific primers and probes for the HNMT, NSF, and PTGS2 genes are presented in Table 1. The specificity of primers and probes was checked using Primer3 and BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/, accessed on 22 August 2023) [36].

Relative gene expression levels in patient samples were calculated using the comparative Ct method ΔΔCt [37]. The protocol of statistical analysis is described in detail, in the work carried out earlier [33].

3. Results

In this study, an analysis of changes in gene expression of ADORA2A, MTA1, PTGDS, HNMT, NSF, and PTGS2 at the mRNA level was performed in the peripheral blood from treated and untreated patients with early stages of PD. To assess the specificity of the observed changes for PD pathogenesis, these genes were also analyzed in a neurological control group including patients with various neurodegenerative diseases. The results of the analysis are presented in Table 2.

As is shown in Table 2, significant results in the groups of patients with early stages of PD were obtained for the ADORA2A, MTA1, HNMT, NSF, and PTGS2 genes. Notably, the obtained expression changes are PD-specific, since the expression levels of these genes in the neurological control group do not differ from the expression levels in healthy controls. In the group of untreated patients with early stages of PD, a decrease in the expression level of the MTA1 gene was detected. An increase of ADORA2A gene expression was observed only in a sample of treated patients with early stages of PD. For the HNMT, NSF, and PTGS2 genes, there was a significant increase in expression in both the untreated PD patient group and the treated PD patient group. Significant changes in expression of the PTGDS gene were found only in the neurological control group.

4. Discussion

The study of mRNA levels changes in the blood represents one strategy for finding biomarkers of early stages of PD and may also help to gain insight into the mechanisms of pathogenesis of the disease. In the present study, gene expression changes of ADORA2A, MTA1, PTGDS, PTGS2, NSF, and HNMT were analyzed in the peripheral blood of treated and untreated patients with early stages of PD. In our previous work, we performed a transcriptome analysis in the peripheral blood of three pairs of monozygotic twins discordant for PD, which revealed a significant increase in gene expression of ADORA2A, MTA1, and PTGDS in twins with PD [24]. As shown in Table 2, significant results in the group of patients with early stages of PD were obtained for the ADORA2A and MTA1 genes. The mRNA levels of the MTA1 and PTGDS genes we obtained in the group of patients with early stages of PD did not coincide with the values obtained in the peripheral blood of twins with PD. This result may be explained by the fact that the twins with PD were in more advanced stages of the disease and had received therapy for a longer period than the treated patients at early stages. In contrast, the expression of the ADORA2A gene encoding the G-protein-coupled adenosine receptor subtype A2A increased in treated patients with early stages of PD as well as in twins with PD. It is known that adenosine A2A receptors can form heterodimeric complexes with DAergic D2 receptors (DRD2). Furthermore, there are antagonistic interactions between the receptors within these complexes [38]. Since in the present study the increase in ADORA2A expression was observed only in treated patients with PD, we assume that this gene is involved in the processes affected by antiparkinsonian drug therapy. This effect may be explained by the fact that the treatment with levodopa or dopamine agonists appears to result in internalization of A2A/DRD2 heterodimers and a compensatory increase in A2A homomers and their signaling. In turn, an increase in ADORA2A expression can lead to the development of dyskinesia in treated PD patients [39].

The MTA1 gene encodes metastasis-associated protein 1, which modulates the expression of target genes by functioning as a corepressor or coactivator [40]. In particular, MTA1 functions as a coactivator of the transcription of the tyrosine hydroxylase gene (TH), the main enzyme of dopamine synthesis (Figure 1) [41]. Table 2 shows that untreated PD patients showed a statistically significant decrease in MTA1 transcript levels. At the same time, the expression of MTA1 increased 1.5-fold in twins with PD relative to healthy twins [24]. The data we obtained can be explained by the fact that the decrease in MTA1 mRNA levels in the early stages of pathogenesis may be a consequence of DAergic neuronal death. In turn, the increased expression of this gene in twins with later stages of PD is explained by the fact that the cell is trying to compensate for the intensity of dopamine synthesis through increased TH expression. Among the published data, only Kumar et al. examined the expression level of MTA1 in PD, which showed a decrease in MTA1 expression in the SN in patients with PD [42]. It is important to note that Kumar’s work used postmortem brain samples. From this, we can assume that the patients had the late most severe stages of PD, when active medication treatment has been passed and comorbidities may be present. It is likely that at even later stages of the disease, the SN cells no longer have the resources necessary to maintain compensatory mechanisms, which accounts for the decrease in MTA1 expression.

We also performed expression analysis for the HNMT, NSF, and PTGS2 genes selected for analysis based on work previously performed in the laboratory and analysis of published data [25, 26].

The HNMT gene encodes an enzyme of histamine metabolism, histamine N-methyltransferase, which methylates histamine in the presence of S-adenosyl-1-methionine to form N-methylhistamine [43]. In our work, we observed an increase in HNMT mRNA levels in the peripheral blood of PD patients. There is evidence that patients with PD are characterized by increased levels of histamine. Thus, increased levels of histamine have been found in postmortem brain samples—in the SN, globus pallidus, and putamen [27]. In addition, elevated histamine levels have been observed in the blood of untreated PD patients [44]. It is known that elevated levels of histamine can contribute to the degeneration of DAergic neurons and trigger inflammatory signaling processes [27, 45]. Histamine through its interaction with histaminergic receptor H1 (HRH1) causes activation of microglia and, eventually, death of DAergic neurons (Figure 2) [46]. In this regard, it can be assumed that the increase in HNMT mRNA expression may be a protective mechanism consisting in the enhancement of metabolism of excessive histamine levels. A similar increase in HNMT mRNA levels was previously reported in the tissues of SN and putamen in PD patients [47].

In our earlier work focused on the analysis of the expression of transport-associated genes in the brain tissues of mice with the MPTP-induced PD model, interesting results were obtained for the NSF gene [26]. We observed a significant increase in mRNA levels of this gene in the SN and striatum tissues in mice with an MPTP-induced model of early PD stage. For this reason, the NSF gene became of interest for us to validate the results on human samples. As shown in Table 2, the expression of the NSF gene increased significantly in the peripheral blood of patients with early stages of PD. This gene encodes an N-ethylmaleimide-sensitive factor that is involved in intracellular membrane fusion. It performs this function by influencing the assembly and disassembly of the SNARE complex [48]. In particular, NSF is involved in neurotransmission, ensuring the fusion of synaptic vesicles to the presynaptic membrane. Evidence is accumulating that NSF is involved in PD pathogenesis [49–51]. Our findings on increased NSF expression in PD patients may indicate the development of compensatory mechanisms resulting in more active vesicular transport.

The greatest change in expression was obtained for the PTGS2 gene. The PTGS2 gene encodes cyclooxygenase-2 (COX2), the main enzyme responsible for the conversion of arachidonic acid into prostaglandin (PG) H2, which is the main precursor of the different PGs, but especially PGE2 [52]. COX2 expression is known to be mainly upregulated by inflammatory stimuli [53]. At present, there is evidence that COX2 is involved in the pathophysiology of PD, but its exact role is still unclear [54]. In studies of mice with MPTP-induced models of PD, COX2 has been shown to have deleterious effects on DAergic neurons [55–58]. It is likely that increasing COX2 levels may contribute to neuronal death via dopamine oxidation followed by dopamine-quinone formation or by increasing PGE2 levels, through which the formation of reactive oxygen species and astrocyte activation will occur [52, 59, 60]. Thus, it can be assumed that the increase in PTGS2 expression that we observed in patients with early stages of PD indicates the development of inflammatory processes, which is likely to lead to even greater death of DAergic neurons and, thereby, enhance neurodegeneration. Our results are consistent with those obtained in some earlier studies. Increased COX2 expression has been found in the SN of mice with MPTP-induced models of PD, as well as in similar samples from PD patients [56].

Thus, we found a total of 4 genes that may be associated with early clinical stages of PD. The role of these genes in the pathogenesis of this disease requires further experimental confirmation. Based on the studied literature data and our results, we assume that at the early stages of PD development, MTA1 and PTGS2 genes are associated with neurodegenerative processes, while HNMT and NSF are involved in the development of compensatory effects (Figure 3).

5. Conclusions

In summary, analysis of changes in gene expression at the mRNA level in the peripheral blood of patients with early stages of PD showed a significant and PD-specific change in the expression of four genes: MTA1, PTGS2, NSF, and HNMT. These genes may be associated with PD pathogenesis in the early clinical stages of the disease. In addition, these genes may be considered as potential biomarkers of PD early stages, but this hypothesis requires further verification in independent patient samples. It is likely that MTA1 and PTGS2 are involved in neurodegenerative processes in the early stages of PD pathogenesis, while HNMT and NSF are involved in the development of compensatory effects. Altered expression of the ADORA2A gene in treated PD patients may indicate that this gene is involved in processes affected by antiparkinsonian therapy. The PTGDS gene is probably not involved in the pathogenesis of PD in the early stages of pathogenesis.

Data Availability

The datasets used during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

The work of Ekaterina Semenova, Margarita Rudenok, Maria Shadrina, and Anelya Alieva was funded by the Russian Science Foundation (RSF) (project no. 20-15-00262). The work of Suzanna Partevian, Marina Shulskaya, and Maria Lukashevich was funded by the state task of the National Research Center “Kurchatov Institute”. The work of Petr Slominsky was supported by the Ministry of Science and Higher Education of the Russian Federation, agreement 075-15-2021-1357 and contract no. 69/21—SIN1357. The work was carried out using the equipment of the Center “Cellular and Genetic Technologies” of the National Research Center “Kurchatov Institute.”

References

R. Balestrino and A. H. V. Schapira, “Parkinson disease,” European Journal of Neurology, vol. 27, no. 1, pp. 27–42, 2020.
View at: Publisher Site | Google Scholar
A. Lee and R. M. Gilbert, “Epidemiology of Parkinson disease,” Neurologic Clinics, vol. 34, no. 4, pp. 955–965, 2016.
View at: Publisher Site | Google Scholar
Group GBDNDC, “Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015,” The Lancet Neurology, vol. 16, no. 11, pp. 877–897, 2017.
View at: Google Scholar
E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007.
View at: Publisher Site | Google Scholar
F. N. Emamzadeh and A. Surguchov, “Parkinson’s disease: biomarkers, treatment, and risk factors,” Frontiers in Neuroscience, vol. 12, p. 612, 2018.
View at: Publisher Site | Google Scholar
W. Poewe, K. Seppi, C. M. Tanner et al., “Parkinson disease,” Nature Reviews. Disease Primers, vol. 3, no. 1, article 17013, 2017.
View at: Publisher Site | Google Scholar
X. S. Zeng, W. S. Geng, J. J. Jia, L. Chen, and P. P. Zhang, “Cellular and molecular basis of neurodegeneration in Parkinson disease,” Frontiers in Aging Neuroscience, vol. 10, p. 109, 2018.
View at: Publisher Site | Google Scholar
L. V. Kalia and A. E. Lang, “Parkinson’s disease,” Lancet, vol. 386, no. 9996, pp. 896–912, 2015.
View at: Publisher Site | Google Scholar
W. Le, J. Dong, S. Li, and A. D. Korczyn, “Can biomarkers help the early diagnosis of Parkinson’s disease?” Neuroscience Bulletin, vol. 33, no. 5, pp. 535–542, 2017.
View at: Publisher Site | Google Scholar
F. Amenta, E. Bronzetti, F. Cantalamessa et al., “Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes,” Journal of Neuroimmunology, vol. 117, no. 1-2, pp. 133–142, 2001.
View at: Publisher Site | Google Scholar
P. Barbanti, G. Fabbrini, A. Ricci et al., “Increased expression of dopamine receptors on lymphocytes in Parkinson’s disease,” Movement disorders: official journal of the Movement Disorder Society, vol. 14, no. 5, pp. 764–771, 1999.
View at: Publisher Site | Google Scholar
B. Caronti, G. Tanda, C. Colosimo et al., “Reduced dopamine in peripheral blood lymphocytes in Parkinson’s disease,” Neuroreport, vol. 10, no. 14, pp. 2907–2910, 1999.
View at: Publisher Site | Google Scholar
C. Pellicano, F. R. Buttarelli, A. Circella et al., “Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor,” Journal of Neural Transmission (Vienna), vol. 114, no. 7, pp. 935–938, 2007.
View at: Publisher Site | Google Scholar
F. R. Buttarelli, A. Fanciulli, C. Pellicano, and F. E. Pontieri, “The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders,” Current Neuropharmacology, vol. 9, no. 2, pp. 278–288, 2011.
View at: Publisher Site | Google Scholar
F. Blandini, E. Sinforiani, C. Pacchetti et al., “Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease,” Neurology, vol. 66, no. 4, pp. 529–534, 2006.
View at: Publisher Site | Google Scholar
E. Mutez, L. Larvor, F. Lepretre et al., “Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation,” Neurobiology of Aging, vol. 32, no. 10, pp. 1839–1848, 2011.
View at: Publisher Site | Google Scholar
M. K. Karlsson, P. Sharma, J. Aasly et al., “Found in transcription: accurate Parkinson’s disease classification in peripheral blood,” Journal of Parkinson's Disease, vol. 3, no. 1, pp. 19–29, 2013.
View at: Publisher Site | Google Scholar
R. Shamir, C. Klein, D. Amar et al., “Analysis of blood-based gene expression in idiopathic Parkinson disease,” Neurology, vol. 89, no. 16, pp. 1676–1683, 2017.
View at: Publisher Site | Google Scholar
S. Shinde and K. Pasupathy, “Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson’s disease: preliminary study,” Neurology India, vol. 54, no. 4, pp. 390–393, 2006.
View at: Publisher Site | Google Scholar
L. Migliore, L. Petrozzi, C. Lucetti et al., “Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients,” Neurology, vol. 58, no. 12, pp. 1809–1815, 2002.
View at: Publisher Site | Google Scholar
F. Blandini, M. Cosentino, A. Mangiagalli et al., “Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson’s disease. The effect of dopaminergic treatment,” Journal of Neural Transmission, vol. 111, no. 8, pp. 1017–1030, 2004.
View at: Google Scholar
R. Calligaris, M. Banica, P. Roncaglia et al., “Blood transcriptomics of drug-naïve sporadic Parkinson’s disease patients,” BMC Genomics, vol. 16, no. 1, p. 876, 2015.
View at: Publisher Site | Google Scholar
S. El Haddad, A. Serrano, F. Moal et al., “Disturbed expression of autophagy genes in blood of Parkinson’s disease patients,” Gene, vol. 738, article 144454, 2020.
View at: Publisher Site | Google Scholar
E. I. Semenova, I. N. Vlasov, S. A. Partevian et al., “Transcriptome profiling reveals differential expression of circadian behavior genes in peripheral blood of monozygotic twins discordant for Parkinson’s disease,” Cells, vol. 11, no. 16, p. 2599, 2022.
View at: Google Scholar
A. K. Alieva, M. M. Rudenok, E. V. Novosadova et al., “Whole-transcriptome analysis of dermal fibroblasts, derived from three pairs of monozygotic twins, discordant for Parkinson’s disease,” Journal of Molecular Neuroscience, vol. 70, no. 2, pp. 284–293, 2020.
View at: Publisher Site | Google Scholar
M. M. Rudenok, M. I. Shadrina, E. V. Filatova et al., “Expression analysis of genes involved in transport processes in mice with MPTP-induced model of Parkinson’s disease,” Life, vol. 12, no. 5, p. 751, 2022.
View at: Publisher Site | Google Scholar
O. V. Anichtchik, J. O. Rinne, H. Kalimo, and P. Panula, “An altered histaminergic innervation of the substantia nigra in Parkinson’s disease,” Experimental Neurology, vol. 163, no. 1, pp. 20–30, 2000.
View at: Publisher Site | Google Scholar
J. O. Rinne, O. V. Anichtchik, K. S. Eriksson et al., “Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy,” Journal of Neurochemistry, vol. 81, no. 5, pp. 954–960, 2002.
View at: Publisher Site | Google Scholar
Movement Disorder Society Task Force on Rating Scales for Parkinson’s D, “The unified Parkinson’s disease rating scale (UPDRS): status and recommendations,” Movement Disorders, vol. 18, no. 7, pp. 738–750, 2003.
View at: Publisher Site | Google Scholar
C. G. Goetz, W. Poewe, O. Rascol et al., “Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations,” Movement Disorders, vol. 19, no. 9, pp. 1020–1028, 2004.
View at: Publisher Site | Google Scholar
A. Alieva, M. Rudenok, E. Filatova et al., “VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson’s disease,” Scientific Reports, vol. 10, no. 1, p. 827, 2020.
View at: Publisher Site | Google Scholar
World Medical A, “World medical association declaration of Helsinki,” JAMA, vol. 310, no. 20, pp. 2191–2194, 2013.
View at: Publisher Site | Google Scholar
A. K. Alieva, E. V. Filatova, A. V. Karabanov, S. N. Illarioshkin, P. A. Slominsky, and M. I. Shadrina, “Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease,” Parkinson’s Disease, vol. 2015, Article ID 294396, 6 pages, 2015.
View at: Publisher Site | Google Scholar
O. Suslov and D. A. Steindler, “PCR inhibition by reverse transcriptase leads to an overestimation of amplification efficiency,” Nucleic Acids Research, vol. 33, no. 20, article e181, 2005.
View at: Publisher Site | Google Scholar
A. K. Alieva, E. V. Filatova, M. M. Rudenok, P. A. Slominsky, and M. I. Shadrina, “Housekeeping genes for Parkinson’s disease in humans and mice,” Cell, vol. 10, no. 9, p. 2252, 2021.
View at: Publisher Site | Google Scholar
D. L. Wheeler, D. M. Church, S. Federhen et al., “Database resources of the National Center for Biotechnology,” Nucleic Acids Research, vol. 31, no. 1, pp. 28–33, 2003.
View at: Publisher Site | Google Scholar
K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C (T)) method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
View at: Publisher Site | Google Scholar
S. N. Schiffmann, G. Fisone, R. Moresco, R. A. Cunha, and S. Ferre, “Adenosine A_2A receptors and basal ganglia physiology,” Progress in Neurobiology, vol. 83, no. 5, pp. 277–292, 2007.
View at: Publisher Site | Google Scholar
K. Fuxe, D. Marcellino, S. Genedani, and L. Agnati, “Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson’s disease,” Movement Disorders, vol. 22, no. 14, pp. 1990–2017, 2007.
View at: Publisher Site | Google Scholar
N. Sen, B. Gui, and R. Kumar, “Physiological functions of MTA family of proteins,” Cancer Metastasis Reviews, vol. 33, no. 4, pp. 869–877, 2014.
View at: Publisher Site | Google Scholar
S. D. N. Reddy, S. K. Rayala, K. Ohshiro et al., “Multiple coregulatory control of tyrosine hydroxylase gene transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 10, pp. 4200–4205, 2011.
View at: Publisher Site | Google Scholar
A. S. Kumar, S. Jagadeeshan, A. Subramanian et al., “Molecular mechanism of regulation of MTA1 expression by granulocyte colony-stimulating factor,” The Journal of Biological Chemistry, vol. 291, no. 23, pp. 12310–12321, 2016.
View at: Publisher Site | Google Scholar
J. R. Horton, K. Sawada, M. Nishibori, and X. Cheng, “Structural basis for inhibition of histamine N-methyltransferase by diverse drugs,” Journal of Molecular Biology, vol. 353, no. 2, pp. 334–344, 2005.
View at: Publisher Site | Google Scholar
M. H. Coelho, I. J. Silva, M. S. Azevedo, and C. F. Manso, “Decrease in blood histamine in drug-treated parkinsonian patients,” Molecular and Chemical Neuropathology, vol. 14, no. 2, pp. 77–85, 1991.
View at: Publisher Site | Google Scholar
C. Q. Liu, Z. Chen, F. X. Liu, D. N. Hu, and J. H. Luo, “Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats,” Neuropharmacology, vol. 53, no. 7, pp. 832–841, 2007.
View at: Publisher Site | Google Scholar
S. M. Rocha, T. Saraiva, A. C. Cristóvão et al., “Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation,” Journal of Neuroinflammation, vol. 13, no. 1, p. 137, 2016.
View at: Publisher Site | Google Scholar
L. Shan, K. Bossers, S. Luchetti et al., “Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study,” Neurobiology of Aging, vol. 33, no. 7, pp. 1488.e1–1488.e13, 2012.
View at: Publisher Site | Google Scholar
C. Zhao, J. T. Slevin, and S. W. Whiteheart, “Cellular functions of NSF: not just SNAPs and SNAREs,” FEBS Letters, vol. 581, no. 11, pp. 2140–2149, 2007.
View at: Publisher Site | Google Scholar
F. Pischedda, M. D. Cirnaru, L. Ponzoni et al., “LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation,” Brain, vol. 144, no. 5, pp. 1509–1525, 2021.
View at: Publisher Site | Google Scholar
E. Belluzzi, A. Gonnelli, M. D. Cirnaru et al., “LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate,” Molecular Neurodegeneration, vol. 11, no. 1, p. 1, 2016.
View at: Publisher Site | Google Scholar
D. T. Babcock, W. Shen, and B. Ganetzky, “A neuroprotective function of NSF1 sustains autophagy and lysosomal trafficking in Drosophila,” Genetics, vol. 199, no. 2, pp. 511–522, 2015.
View at: Publisher Site | Google Scholar
P. Teismann, “COX-2 in the neurodegenerative process of Parkinson’s disease,” BioFactors, vol. 38, no. 6, pp. 395–397, 2012.
View at: Publisher Site | Google Scholar
N. N. Rumzhum and A. J. Ammit, “Cyclooxygenase 2: its regulation, role and impact in airway inflammation,” Clinical and Experimental Allergy, vol. 46, no. 3, pp. 397–410, 2016.
View at: Publisher Site | Google Scholar
L. Minghetti, “Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 9, pp. 901–910, 2004.
View at: Publisher Site | Google Scholar
Z. H. Feng, T. G. Wang, D. D. Li et al., “Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra,” vol. 329, no. 3, pp. 354–358, 2002.
View at: Publisher Site | Google Scholar
P. Teismann, K. Tieu, D. K. Choi et al., “Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5473–5478, 2003.
View at: Publisher Site | Google Scholar
P. Teismann and B. Ferger, “Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease,” Synapse, vol. 39, no. 2, pp. 167–174, 2001.
View at: Publisher Site | Google Scholar
N. Aubin, O. Curet, A. Deffois, and C. Carter, “Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice,” Journal of Neurochemistry, vol. 71, no. 4, pp. 1635–1642, 1998.
View at: Publisher Site | Google Scholar
T. G. Hastings, “Enzymatic oxidation of dopamine: the role of prostaglandin H synthase,” Journal of Neurochemistry, vol. 64, no. 2, pp. 919–924, 1995.
View at: Publisher Site | Google Scholar
S. W. Chae, B. Y. Kang, O. Hwang, and H. J. Choi, “Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells,” Neuroscience Letters, vol. 436, no. 2, pp. 205–209, 2008.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Ekaterina I. Semenova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

320

Downloads

352

Citations